Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease
Conditions
Keywords
DeSyne, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease
Brief summary
The purpose of this study is to evaluate effectiveness and safety of DESyne in Routine Clinical Practice
Interventions
DEVICEDeSyne drug eluting stent group
Sponsors
CardioVascular Research Foundation, Korea
Amg Korea Co. Ltd.
Seung-Jung Park
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 20 and more * Intervention with DeSyne drug eluting coronary stent * Agreed with written informed consent form
Exclusion criteria
* Intervention with DeSyne drug eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite event rate | 1year | Death, non fatal myocardial infarction, Target Vessel Revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac death | 5year | — |
| Myocardial infarction | 5year | — |
| Composite event of death or myocardial infarction | 5year | — |
| Composite event of cardiac death or myocardial infarction | 5year | — |
| All death | 5year | — |
| Target Lesion revascularization | 5year | — |
| Stent thrombosis | 5year | stent thrombosis as classified by an Academic Research Consortium |
| Stroke | 5year | — |
| Procedural success | 3day | defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. |
| Target Vessel revascularization | 5year | — |
Countries
South Korea
Outcome results
None listed